In a positive development for Aurobindo Pharma, the company witnessed a rise in share prices during the opening trade on January 9 following the receipt of an establishment inspection report from the US Food and Drug Administration (USFDA).
As of 9:46 am the shares were trading 0.55% higher at ₹1,121.00
The coveted VAI classification by the FDA signifies that no objectionable conditions or practices were identified during the inspection, or any conditions found do not warrant further regulatory action. Described as the best possible outcome, this designation indicates that the Chitkul facility is deemed fit to operate without any immediate regulatory concerns, reinforcing investor confidence in Aurobindo Pharma’s regulatory compliance and manufacturing capabilities.
